<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358224</url>
  </required_header>
  <id_info>
    <org_study_id>R668-AD-1830</org_study_id>
    <nct_id>NCT04358224</nct_id>
  </id_info>
  <brief_title>The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment</brief_title>
  <official_title>The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonathan A. Bernstein, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bernstein Clinical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The utility of functionally relevant signature genes in assessing the clinical outcomes of
      dupilumab treatment in the adult onset atopic dermatitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of 9 visits. Duplimab will used in the treatment of adult onset atopic
      dermatitis. Qualified subjects will receive 5 dupilumab open-label injections. Skin biopsies/
      skin strips will be obtained at the beginning and the end of treatment. TARC and IgE levels
      will be obtained at the beginning and end of treatment. Subjects will complete daily diaries
      assessing atopic dermatitis symptoms. Patient reported out comes will be completed at each
      visit
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">May 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to correlate cutaneous transcriptomes with before and after Dupilumab treatment outcomes in patients who meet the clinical diagnostic criteria for adult onset AD.</measure>
    <time_frame>after 6 months</time_frame>
    <description>Data will be analyzed from skin punch biopsies from active skin lesions and uninvolved skin samples before and after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate possible influence of Dupilumab on serologic protein biomarkers in patients with adult onset AD</measure>
    <time_frame>after 6 months</time_frame>
    <description>Total IgE, TARC and eotaxin will be compared pre and post treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Atopic Dermatitis</condition>
  <condition>Eczema</condition>
  <arm_group>
    <arm_group_label>open-label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>open-label</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dupilumab Prefilled Syringe</intervention_name>
    <description>open-label</description>
    <arm_group_label>open-label</arm_group_label>
    <other_name>dupixent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  history of adult onset atopic dermatitis

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Bernstein</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bernstein Clinial Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Berendts</last_name>
    <phone>513-354-1746</phone>
    <email>kberendts@bernsteincrc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bernstein Clinical Research Center</investigator_affiliation>
    <investigator_full_name>Jonathan A. Bernstein, MD</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>to be determined</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>at end of trial</ipd_time_frame>
    <ipd_access_criteria>to be determined</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

